Sandoz Family Pares Novartis Stake With $2.9 Billion Sale
Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...
Sandoz Family to Get $2.9 Billion From Offloading Part of Its Novartis Stake
ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling ...
Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company") today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for the ...
Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...
Avecho Biotechnology: Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in AustraliaAvecho ...
Sandoz to pay $275 million to settle drug price-fixing case
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...
NOLA.com6h
The Rex court will watch the parade from a new spot this year, sporting a rainbow of shades
When Rex, the king of Carnival, majestically rolls from his den on South Claiborne Avenue and turns down Napoleon Avenue, the ...
The Pharma Letter7d
Sandoz launches biosimilar Pyzchiva in USA
Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...
Sandoz Group Ltd (SDZXF) Receives a Hold from UBS
In a report released today, Harry Sephton from UBS maintained a Hold rating on Sandoz Group Ltd (SDZXF – Research Report), with a price target ...
EconoTimes4d
Sandoz Family’s Emasan AG Sells Novartis Stake for $2.9 Billion in Major Cash-Out
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis ...
Reuters5d
Sandoz family to get $2.9 billion from offloading part of its Novartis stake
ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...